Skip Nav Destination
Impact of the ICAL on the treatment of acute leukemia
Should minimal residual disease negativity be the end point of myeloma therapy?
Should minimal residual disease negativity not be the end point of myeloma therapy?
Index case of acute myeloid leukemia in a family harboring a novel CEBPA germ line mutation
Issue Archive
Table of Contents
BLOOD ADVANCES TALK
Impact of the ICAL on the treatment of acute leukemia
Global Advances
POINT-COUNTERPOINT
Should minimal residual disease negativity be the end point of myeloma therapy?
Clinical Trials & Observations
Should minimal residual disease negativity not be the end point of myeloma therapy?
Clinical Trials & Observations
EXCEPTIONAL CASE REPORT
Index case of acute myeloid leukemia in a family harboring a novel CEBPA germ line mutation
Clinical Trials & Observations
STIMULUS REPORT
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
-
Cover Image
Cover Image
![issue cover]()
COVER FIGURE
In silico PyMOL modeling showing a representation of the normal nonactivated αIIb (purple) and β3 (green) transmembrane and cytoplasmic tail segments, highlighting amino acids engaged in the inner membrane association clasp. A single-amino-acid β3 Leu718 deletion detected in a patient with inherited macrothrombocytopenia and defective platelet aggregation changes the synchronization of the αIIbβ3 cytoplasmic tails and weakens the clasp. See the article by Nurden et al. - PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
